Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer

15 May 2025

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICIs) are becoming more prominent in the treatment of gastric cancer (GC). However, predictive biomarkers of response to ICIs in HER2-negative patients remain incompletely understood. METHODS: A total of 47 patients diagnosed with HER2-negative advanced GC who underwent ICI regimens were eligible for this study. Plasma samples with paired white blood cells prior to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40372586
DOI: 10.1007/s10120-025-01621-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancerPMID 40372586Read ↗

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapiesSemantic proximity Read ↗

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitorsSemantic proximity Read ↗

Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.Semantic proximity Read ↗

PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.Semantic proximity Read ↗

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Semantic proximity Read ↗

Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.Semantic proximity Read ↗

The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.Semantic proximity Read ↗

Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancers.Semantic proximity Read ↗

Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.Semantic proximity Read ↗

Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.Semantic proximity Read ↗

Circulating Tumor DNA Mutation Profiling Reveals Prognostic Signatures in Breast CancerSemantic proximity Read ↗

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.